Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis

Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomarkers to inform the optimal choice for individual patients. Her...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	David P Carbone, David Spigel, Jeffrey S Ross, Karthikeyan Murugesan, Gerald Li, Richard S P Huang, Ryon P Graf, Geoffrey R Oxnard, Alexa Schrock, Liangliang Zhang, Khaled Tolba, Jacob Sands
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-01-01
Online Access:	https://jitc.bmj.com/content/11/1/e005801.full

Similar Items

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
by: Jie He, et al.
Published: (2023-11-01)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
by: Kim Monkhorst, et al.
Published: (2022-02-01)

一种新的高灵敏的HRP-TMB成色法(TMB-ST)
Published: (1989-01-01)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
by: Chen Zhao, et al.
Published: (2020-05-01)

Authors response to “Letter to the Editor”: “Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types”
by: David R Gandara, et al.
Published: (2025-07-01)

Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy
by: Yu Wang, et al.
Published: (2024-06-01)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
by: Jeffrey S Ross, et al.
Published: (2022-10-01)

Parsimoniously Fitting Large Multivariate Random Effects in glmmTMB
by: Maeve McGillycuddy, et al.
Published: (2025-04-01)

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays
by: Danyi Wang, et al.
Published: (2023-10-01)

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC
by: Nicolas Roussot, et al.
Published: (2024-08-01)

Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy
by: Ya-Ru Miao, et al.
Published: (2022-09-01)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
by: Jiayan Wei, et al.
Published: (2021-10-01)

Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC
by: Arter ZL, et al.
Published: (2025-02-01)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
by: Vamsi Parimi, et al.
Published: (2023-01-01)

Implementing TMB measurement in clinical practice: considerations on assay requirements
by: Reinhard Büttner, et al.
Published: (2019-02-01)

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN
by: Saori Mishima, et al.
Published: (2023-09-01)

Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma
by: Guifu Wu, et al.
Published: (2024-03-01)

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
by: Vivek Subbiah, et al.
Published: (2025-02-01)

33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis
by: Nicole Zhang, et al.
Published: (2023-11-01)

TMB‐High, MSI‐High Castration‐Resistant Prostate Cancer Treated With Pembrolizumab
by: Satoshi Muraoka, et al.
Published: (2025-09-01)

Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report
by: Nils C. H. van Creij, et al.
Published: (2025-03-01)

Pembrolizumab and olaparib in a cisplatin-refractory testicular cancer patient with a high TMB: first case report
by: Nils C. H. van Creij, et al.
Published: (2025-03-01)

TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors
by: Xin Lai, et al.
Published: (2025-01-01)

Seismic Attribute Analysis for Prospect Delineation in ‘TMB’ Field, Niger Delta Basin, Nigeria
by: O. J. Allo, et al.
Published: (2022-06-01)

Computational, optical and feasibility studies of organic luminescence TMB-PPT blend for photovoltaic application
by: Tejas Sharma, et al.
Published: (2024-02-01)

Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB
by: Mingyu Li, et al.
Published: (2023-02-01)

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1
by: Zachary D. Wallen, et al.
Published: (2024-11-01)

Different NGS identification methods of somatic mutation sites in solid tumors impact TMB results
by: Xueshu Chen, et al.
Published: (2025-03-01)

MS-stable/TMB-high pleomorphic liposarcoma successfully treated with pembrolizumab: a case report
by: Satoshi Miwa, et al.
Published: (2025-06-01)

Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
by: Saumya D. Sisoudiya, et al.
Published: (2024-07-01)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
by: Michael Cekay, et al.
Published: (2023-08-01)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
by: Chuan Wang, et al.
Published: (2022-03-01)

CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer
by: Jiexiao Wang, et al.
Published: (2024-02-01)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)

876 Self-replicating RNA therapeutics for off-the-shelf precision immunotherapy targeting acquired resistance mutations in low TMB tumors
by: Erika J Crosby, et al.
Published: (2023-11-01)

TMB Signature-Related RCAN2 Promotes Apoptosis by Upregulating EHF/DR5 Pathway in Hepatocellular Carcinoma
by: Yu-Jie Xu, et al.
Published: (2024-07-01)

Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
by: Wuwu Ding, et al.
Published: (2024-01-01)

Utilizing Nanoparticle Catalyzed TMB/H2 O2 System for Determination of Aspirin in Exhaled Breath Condensate
by: Samineh Mohammadzadeh Abachi, et al.
Published: (2023-07-01)

The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma
by: Yong Cheng, et al.
Published: (2021-02-01)

Chemical Behavior of Mo2TMB2 (TM = Fe, Co, Ni) upon the Oxygen Evolution Reaction (OER)
by: Fatma Aras, et al.
Published: (2025-06-01)